Also, the American's financial situation is very different to that of Dubai & Australia - maybe not Europe.
I am sure MR stated in the past, that he expects CVAC to be used in other duristictions BEFORE FDA approval in USA.
So, I would see the company's very important job being to negotiate cost/price structures that meet the needs of patients, the company & those using CVAC. After all, it really will meet an unmet need.
My only concern is the cost of setting up manufacturing plants & the passed on costs to whichever consumers use CVAC.
But DNDN appear to have clearly misled investors - one thing I will say about Prima - they have always understated their potential, as opposed to ovestating it - and that has to be looked at as a positive. Even if the chart (TA) doesn't look positive atm.
Spare Paper
PRR Price at posting:
15.7¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)